摘要
Abstract
Objective:To investigate the effect of Low Molecular Heparin sequential Rivaroxaban in the treatment of patients with pulmonary embolism.Methods:The clinical data of 60 patients with pulmonary embolism admitted to Jiangsu Province(Suqian)Hospital from January 2021 to December 2023 were retrospectively analyzed,all patients were treated with Low Molecular Heparin sequential Rivaroxaban for 3 months.Symptom remission time and changes in vital signs,myocardial markers and coagulation function were analyzed.Results:After treatment,dyspnea and cyanosis were relieved at(5.56±1.12)d and(6.35±1.24)d,respectively.After treatment,the respiratory rate and heart rate of patients were lower than before treatment,and PaO2 was higher than before treatment,with statistical significance(P<0.05).After treatment,the levels of N-terminal brain natriuretic peptide precursors and troponinⅠ were lower than those before treatment,with statistical significance(P<0.05).After treatment,the D-dimer indexes of patients was lower than before treatment,with statistical significance(P<0.05).Conclusion:The use of Low Molecular Heparin sequential Rivaroxaban in the treatment of pulmonary embolism patients can improve vital signs,coagulation function indicators,myocardial markers and alleviate clinical symptoms,and the clinical effect is good.关键词
肺栓塞/低分子肝素/症状缓解时间/利伐沙班/心肌标记物/生命体征Key words
Pulmonary embolism/Low Molecular Heparin/Time to symptom relief/Rivaroxaban/Myocardial markers/Vital signs分类
医药卫生
